Study guide
1.3 Staff Training, Qualifications & Delegation of Authority Log (DOAL)
ACRP Certified Professional ACRP-CP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: GCP Principles, Roles & Delegation
1.1 The Eleven ICH E6(R3) Principles of GCP & Guideline Structure 1.2 Sponsor & Investigator Responsibilities and Delegation of Authority 1.3 Staff Training, Qualifications & Delegation of Authority Log (DOAL) 1.4 CRO Oversight, Vendor Management & Transfer of Regulatory Obligations (TORO)
2 Chapter 2: Essential Records, Source Documentation & Data Confidentiality
2.1 Essential Records Before, During and After the Trial (ICH E6(R3) Appendix C) 2.2 Trial Master File (TMF) and Investigator Site File (ISF) Structure & Inspection Readiness 2.3 Source Documentation, ALCOAC Principles & Medical Record Standards 2.4 Confidentiality, Privacy & Protection of Participant Personal Information
3 Chapter 3: Monitoring, Quality Management & Audits
3.1 Risk-Based Quality Management (RBQM) & Quality Management Systems (QMS) 3.2 Monitoring Visit Types: Site Selection, SIV, IMV, and Close-Out 3.3 Risk-Based Monitoring (RBM), Centralized Monitoring & Source Data Verification (SDV vs SDR) 3.4 Quality Audits, Regulatory Inspections, Non-Compliance & Root Cause Analysis / CAPA
4 Chapter 4: Site Feasibility, Start-Up, Facilities & Laboratory Operations
4.1 Site Feasibility Assessment, Capability Analysis & Investigator Selection 4.2 Contractual Agreements: Clinical Trial Agreements, Budgets, Indemnification & Financial Arrangements 4.3 Site Initiation Preparation, System Access & Regulatory Greenlight 4.4 Protocol Review, Operational Feasibility & Institutional Approvals 4.5 Site Facilities, Equipment Maintenance, Calibration & Trial Supplies 4.6 Biological Samples & Hazardous Goods: Collection, Storage, Disposal & Shipment
5 Chapter 5: Subject Recruitment, Retention & Study Visits
5.1 Subject Recruitment Strategies, Advertising Guidelines & Ethical Constraints 5.2 Screening, Eligibility Verification & Inclusion/Exclusion Adherence 5.3 Subject Retention, Compliance, Visit Scheduling & Protocol Window Management 5.4 Managing Lost to Follow-Up, Subject Withdrawal & Early Termination Procedures
6 Chapter 6: Protocol Compliance, Deviations & Site Close-Out
6.1 Protocol Compliance, Waivers vs. Violations & Deviation Management 6.2 Investigational Site Close-Out Activities & Final Reconciliations 6.3 Record Retention, Archiving Requirements & Post-Trial Responsibilities
7 Chapter 7: Research Ethics, Vulnerable Populations & Research Integrity
7.1 Historical Milestones: Nuremberg Code, Belmont Report & Declaration of Helsinki 7.2 Ethical Principles: Beneficence, Non-Maleficence, Autonomy, Justice & Equipoise 7.3 Vulnerable Populations (Pediatrics, Pregnant Women, Prisoners, Cognitively Impaired, Economically Disadvantaged) 7.4 Conflict of Interest, Research Misconduct & Fraud in Clinical Research
8 Chapter 8: Informed Consent & Institutional Review Boards (IRB/IEC)
8.1 Informed Consent Elements, Process & Ongoing Consent / Re-Consent Requirements 8.2 Assent in Minors & Legally Acceptable Representative (LAR) Requirements 8.3 IRB/IEC Composition, Functions, Review Types (Full, Expedited, Exempt) & Continuing Review
9 Chapter 9: Safety Reporting & Adverse Event Management (ICH E2A)
9.1 Adverse Events (AE) vs. Adverse Drug Reactions (ADR) & Serious Adverse Events (SAE) Definitions 9.2 Causality Assessment, Expectedness, Reference Safety Information (RSI) & SUSARs 9.3 Expedited Reporting Timelines (7-day fatal/life-threatening, 15-day other serious) & Periodic Safety Updates (DSUR)
10 Chapter 10: Investigational Product (IP) Management & Accountability
10.1 Investigational Product Lifecycle, Labeling, Packaging & Blinding Procedures 10.2 IP Shipping, Receipt, Temperature Monitoring, Excursion Handling & Chain of Custody 10.3 IP Storage, Dispensing, Accountability Logs & Destruction/Return Procedures 10.4 Emergency Unblinding (Code Breaking) Protocols & Subject Safety Procedures
11 Chapter 11: Regulatory Frameworks, Submissions & Product Reference Information
11.1 Stakeholders, Regulatory Institutions & Global Frameworks in Clinical Research 11.2 Protocol Submission, Approval & Amendment Processes 11.3 Investigator's Brochure, Instructions for Use & Reference Product Information 11.4 Regulatory Reporting Requirements Before and After Marketing Authorisation
12 Chapter 12: Clinical Data Management, EDC & Electronic Records
12.1 Electronic Data Capture (EDC), eCRF Design & Clinical Data Management Systems (CDMS) 12.2 Computerised Systems, Data Governance & Audit Trails (ICH E6(R3) Annex 1 §4) 12.3 Data Validation, Edit Checks, Discrepancy / Query Management & Resolution 12.4 Medical Coding (MedDRA, WHO Drug), SAE Reconciliation, Data Transfer & Database Lock
13 Chapter 13: Trial Design, Biostatistics, Data Monitoring & Transparency
13.1 Phases of Clinical Research (Phase 0, I, II, III, IV) & Translational Medicine 13.2 Study Designs: Parallel, Crossover, Factorial, Adaptive & Non-Inferiority / Equivalence 13.3 Randomization Schemes, Stratification, Blinding Methods & Minimizing Bias 13.4 Endpoints (Primary, Secondary, Surrogate, Composite), Sample Size & Biostatistical Concepts (p-values, CI, ITT vs PP) 13.5 Interim Analyses, DSMB/IDMC Oversight & Efficacy and Safety Evaluation Milestones 13.6 Trial Registration, Results Transparency & Communicating Results to Participants
1.3 Staff Training, Qualifications & Delegation of Authority Log (DOAL)
Key Takeaways Explain This Topic AI
ICH E6(R3) Annex 1 sections 2.3.1 and 2.3.2 explicitly mandate that the Principal Investigator is responsible for supervising all individuals and third parties to whom trial-related duties are delegated.
The Delegation of Authority Log (DOAL) must prospectively capture staff roles, specific task codes, specimen signatures/initials, start/end dates, and PI authorizing signatures.
Retrospective delegation—where staff perform protocol procedures before documented training is completed or before PI authorization—is a critical inspection violation.
Tasks requiring clinical and diagnostic judgment (e.g., AE causality assessment, inclusion/exclusion medical eligibility, physical exams) can only be delegated to qualified, licensed medical professionals.
Site staff turnover requires immediate, structured remediation: end-dating departed personnel, terminating system credentials, and prospectively training and onboarding replacements.
Last updated: August 2026
Staff Training, Qualifications & Delegation of Authority Log (DOAL)
Core Regulatory Mandate: Under ICH E6(R3) Annex 1 section 2.3.1, "The investigator is responsible for supervising any individual or any party to whom the investigator delegates trial-related duties and functions conducted at the trial site." Under Section 4.2.6, "If the investigator/institution retains the services of any individual or party to undertake trial-related duties and functions, the investigator/institution should ensure that this individual or party is qualified... and should ensure an integrity system is maintained."
Failure to properly delegate, train, and supervise trial site personnel is the single most common category of FDA Form 483 observations and Warning Letters issued to clinical investigators. Master the mechanics of the Delegation of Authority Log (DOAL), qualification verification, and training workflows.
1. Anatomy of the Delegation of Authority Log (DOAL)
The Delegation of Authority Log (DOAL) (also termed the Site Delegation Log, Signature and Delegation Log, or Responsibility Log) is a living regulatory document maintained within the Investigator Site File (ISF) . ┌───────────────────────────────────────────────────────────────────────────┐
- │ MANDATORY DOAL ELEMENTS │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 1. Protocol Identification: Protocol number, title, and site number │
- │ 2. Principal Investigator Name & Signature: Confirms site leadership │
- │ 3. Staff Member Details: Full printed name and institutional role │
- │ 4. Standardized Task Assignment Codes: Specific authorized activities │
- │ 5. Specimen Signature & Initials: To authenticate paper/eSource entries │
- │ 6. Task Start Date: Must be ON or BEFORE any protocol task is performed │
- │ 7. Task End Date: Mandatory when a staff member departs or changes roles │
- │ 8. PI Authorization Signature & Date: Confirms prospective delegation │
- └───────────────────────────────────────────────────────────────────────────┘
- The Cardinal Rule: Prospective Authorization
Delegation is prospective, never retroactive .
Step 1: Staff member submits CV, active medical license, and GCP certificate.
Step 2: Staff member completes protocol-specific training (documented on training log).
Step 3: Staff member signs and initials the DOAL.
Step 4: Principal Investigator signs and dates the DOAL authorizing the specific tasks.
Step 5: Staff member may now perform the delegated tasks.
Inspection Pitfall: If a study coordinator obtains informed consent on August 10th, but the PI did not sign and date the DOAL authorizing that coordinator for consent until August 15th, an auditor will cite unauthorized conduct of research / invalid consent execution .
2. Standardized Task Codes & Scope of Practice
Delegation must align strictly with the individual's licensure, institutional credentials, education, and legal scope of practice . A PI cannot delegate a task to an individual who is not legally qualified to perform it under state or national law, regardless of their protocol-specific training.
Task Code Clinical Trial Activity Permissible Roles Strictly Prohibited Roles
Code A Informed Consent Discussion & Signature PI, Sub-I (MD/DO/NP/PA), Certified CRC / Research Nurse (if permitted by IRB/SOP) Non-research staff, Phlebotomists, Administrative Data Clerks
Code B Physical Examinations & Medical History Licensed Physician (MD/DO), Nurse Practitioner (NP), Physician Assistant (PA) Registered Nurses (RN without NP credentials), Study Coordinators, PhDs
Code C Inclusion / Exclusion Eligibility Verification Licensed Physician (PI or Sub-I MD/DO) Study Coordinators, Research Nurses, Lab Technicians
Code D Adverse Event Evaluation & Causality Licensed Physician (PI or Sub-I MD/DO) Non-physician Study Coordinators, Data Managers, Phlebotomists
Code E Investigational Product Prescribing / Ordering Licensed Prescriber (MD/DO, or NP/PA with prescribing authority) Study Coordinators, Pharmacists (unless under formal collaborative protocol)
Code F Investigational Product Dispensing & Reconciliation Unblinded Pharmacist, Research Pharmacist, Blinded Dispenser Unqualified site administrative staff
Code G Investigational Product Administration Licensed RN, LPN, Physician, or Certified Infusionist Non-clinical study coordinators, Data entry personnel
Code H Electronic Data Capture (EDC) Entry & Queries Study Coordinators, Data Coordinators, PIs, Sub-Is External monitors, Unblinded monitors on blinded forms
Code I Biological Sample Processing & IATA Packaging Certified IATA/DOT Lab Technicians, Trained CRCs Untrained personnel lacking hazardous materials shipping certification
3. Essential Staff Qualifications & Documentation
For every individual listed on the DOAL, the Investigator Site File (ISF) must contain verifiable proof of competence before that individual engages in trial activities: ┌───────────────────────────────────────────────────────────────────────────┐
- │ MANDATORY CREDENTIALS IN THE ISF │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ • Signed & Dated Curriculum Vitae (CV): Current (updated within 2 years) │
- │ • Active Professional Licensure: Verified MD, DO, RN, NP, PA, RPh licenses│
- │ • Good Clinical Practice (GCP) Training: TransCelerate-recognized cert │
- │ • Human Subjects Protection (HSP) Training: CITI / NIH / Institutional │
- │ • Protocol-Specific Training Log: Signed on current protocol version │
- │ • Role-Specific Certifications: IATA Dangerous Goods, BLS/ACLS, Lab Certs│
- └───────────────────────────────────────────────────────────────────────────┘
- Documenting Protocol Amendments
When a sponsor issues a protocol amendment (e.g., changing dosing schedules, adding new safety labs, or altering inclusion criteria):
All active site personnel must be retrained on the amended protocol.
A new Protocol Training Log must be signed and dated by all staff prior to managing subjects under the amended protocol.
The PI must verify that the IRB has approved the amendment before implementing changes.
4. Managing Site Staff Turnover
Staff turnover is a major vulnerability during multi-year clinical trials. Sites must implement a rigorous Standard Operating Procedure (SOP) whenever personnel depart or new personnel join. ┌───────────────────────────────────────────────────────────────────────────┐
- │ STAFF TURNOVER REMEDIATION WORKFLOW │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ DEPARTING STAFF: │
- │ 1. Enter exact "End Date" on the DOAL. │
- │ 2. PI initials/dates the departure entry. │
- │ 3. Notify Sponsor/CRO to deactivate user accounts in EDC, IVRS, and eTMF.│
- │ 4. Conduct handover meeting and reallocate active subjects. │
- │ │
- │ NEW REPLACEMENT STAFF: │
- │ 1. Collect and file signed CV, active license, and GCP/HSP certificates. │
- │ 2. Complete comprehensive protocol and system-specific training. │
- │ 3. Enter new staff details, task codes, and specimen signature on DOAL. │
- │ 4. PI signs and dates authorization line (PROSPECTIVE GREENLIGHT). │
- │ 5. Request system credentials from Sponsor/CRO. │
- └───────────────────────────────────────────────────────────────────────────┘
- Realistic Clinical Scenario: The Retrospective Delegation Trap
Scenario: A clinical trial site is conducting a Phase III diabetes study. The primary study coordinator goes on emergency medical leave. The PI hires an experienced research nurse, Nurse Jenkins, who holds active RN licensure and current GCP certification. On her first day (October 1st), Nurse Jenkins conducts Visit 4 for Subject 108, performing informed consent for an amended protocol, obtaining vital signs, drawing PK blood, and entering data into the EDC system. On October 10th, the PI conducts his bi-weekly site visit, reviews Nurse Jenkins' work, adds her to the DOAL with a start date backdated to October 1st, and signs the log.
Audit & Inspection Findings:
Unqualified/Unauthorized Consent & Study Conduct: Between October 1st and October 10th, Nurse Jenkins performed trial tasks without documented protocol training and without prospective PI delegation authorization.
Backdating / Data Integrity Violation: The PI's backdating of the DOAL constitutes a deliberate documentation violation.
Inspection Result: During a BIMO (Bioresearch Monitoring) inspection, the FDA investigator issues a Form FDA 483 citation for failure to supervise the study and failure to ensure proper informed consent execution.